Alirocumab: Focus on high CV risk patients and mortality outcomes in Odyssey

Classes Cardiology Alirocumab: Focus on high CV risk patients and mortality outcomes in Odyssey

Instructions

This class is not for your profession.

Introduction

Insights from the clinical program of Odessey showing the positive results of CV outcomes on very high risk patients category with significant reduction for the first time in all cause death .

Call Center          920008161

[email protected]

About Us
Support
Technical Requirements
VMA Team
Brand Guidelines
© VMA 2026